Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.
about
Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide TreatmentAn Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2.Cancer-type dependent expression of CK2 transcripts.Therapeutic targeting of CK2 in acute and chronic leukemias.
P2860
Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.
@en
Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.
@nl
type
label
Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.
@en
Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.
@nl
prefLabel
Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.
@en
Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.
@en
P2093
Emilio Itarte
Jordi Vilardell
Laura Ferrer-Font
Lorenzo A Pinna
Lucia Villamañan
Maria Plana
Nuria Arias-Ramos
P2860
P356
10.3390/PH10010024
P577
2017-02-12T00:00:00Z